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EnzymeAbstract This study focused on the synthesis and characterization of hydrazide ligands and their
respective Pd(II) complexes and used high throughput screening to determine their a-glucosidase
and carbonic anhydrase II enzyme inhibition activities. The physical, analytical (elemental analyses
for C, H, N and Pd) and spectral (FT-IR, 1H NMR, 13C NMR, EI-mass) techniques utilized during
characterization revealed the formation of square planar, neutral and 1:2 Pd(II)-hydrazide com-
plexes with the general formula [PdL2Cl2]. In these Pd(II) complexes, the hydrazide ligands are
monodentate; the terminal nitrogen is the donor atom. The uncoordinated hydrazide ligands were
inactive against both a-glucosidase and carbonic anhydrase II enzymes; however, the respective
Pd(II)-hydrazide complexes were approximately 300 times more potent a-glucosidase inhibitors
than the standard compound, 1-deoxynojirimycin (DNJ). Some of the Pd(II) complexes also
demonstrated potential carbonic anhydrase (CA) inhibition properties comparable to the standard
compound, acetazolamide (ACZ).
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus (DM) is a well-known, progressive endocrine
disorder associated with increased morbidity and mortality, as
well as high health care costs. There were approximately 171
million cases of DM in 2000, and this number is expected to
more than double over the next 25 years, reaching 366 million
by 2030 (Funke and Melzig, 2006; Si et al., 2010). This increas-
ing trend has become a serious worldwide medical concern that
stimulates the search for new therapeutic agents.
Scheme 1 General procedure for the synthesis of ligands 1–11.
Studies of Pd(II)-hydrazide complexes 489DM is characterized by hyperglycemia and alterations in
carbohydrate, protein, and lipid metabolisms, caused by
defects in insulin production or action (Jaiswal et al., 2012).
Postprandial hyperglycemia is a prominent defect that occurs
early in diabetes (Carroll et al., 2003) and may lead to various
secondary complications, including elevated risk for cardio-
vascular diseases (Slama et al., 2006), atherosclerosis, catar-
acts, retinopathy, neuropathy, nephropathy and impaired
wound healing (Atta-ur-Rahman et al., 2007). Ingesting a car-
bohydrate-rich diet triggers elevated blood glucose levels due
to the rapid absorption of carbohydrates, which is aided by
glycoside hydrolases, such as alpha-glucosidase (EC
3.2.1.20); this enzyme is present in the epithelial mucosa of
the small intestine and cleaves the glycosidic bonds in complex
carbohydrates to release absorbable monosaccharides (Chiba,
1997). One therapeutic approach for treating diabetes involves
controlling postprandial hyperglycemia by inhibiting the
alpha-glucosidase in the digestive tract, delaying and prolong-
ing the overall carbohydrate digestion time. Slowing car-
bohydrate digestion should reduce the rate of glucose
absorption and consequently prevent spikes in the postpran-
dial blood glucose and insulin levels (Kim et al., 2008;
Chiasson and Rabasa Lhoret, 2004). Using a-glucosidase inhi-
bitors has become a promising therapeutic strategy for reduc-
ing the risks of diabetes and other carbohydrate-mediated
diseases, including hyperlipoproteinemia and obesity (Franco
et al., 2002; Braun et al., 1995; Dwek et al., 2002; Sou et al.,
2001; Mehta et al., 1998; Karpas et al., 1988; Zitzmann
et al., 1999; Truscheit et al., 1981; Madariaga et al., 1988;
Lajolo et al., 1984; McCulloch et al., 1983).
Carbonic anhydrases (CA, EC 4.2.1.1) are zinc-containing
metalloproteins. These enzymes reversibly catalyze the conver-
sion of carbon dioxide to bicarbonate ions (Tripp et al., 2001).
CAs form a group of catalytic enzymes that are vital for many
physiological processes, including respiration and carbon diox-
ide/bicarbonate transport between the lungs and metabolizing
tissues. These enzymes are also involved in important biologi-
cal and patho-physiological functions, such as tumorigenicity,
gluconeogenesis, bone resorption, lipogenesis, calcification,
ureagenesis and electrolyte secretion, as well as carbon dioxide
and pH homeostasis (Ho et al., 2003). This enzymatic family
contains potential therapeutic targets for many diseases.
Currently, CA inhibitors are first line treatments for neurologi-
cal disorders, osteoporosis, glaucoma, cancer and obesity, as
well as gastric and duodenal ulcers; CA inhibitors may also
act as diuretics and antiepileptics (Supuran et al., 2004, 2003;
Supuran and Scozzafava, 2000). CA inhibitors have the ability
to dilate retinal capillaries and suppress capillary blockage
(Mirshafiey and Boghozian, 2011).
Several metal ions and their complexes exhibit diverse bio-
logical activities, including antidiabetic effects (Schwarz and
Mertz, 1959; Rubenstein et al., 1962; Coulston and
Dandona, 1980; Heyliger et al., 1985; Sakurai et al., 1990;
Yoshikawa et al., 2000; Ueda et al., 2005; Ashiq et al.,
2008), as well as phosphodiesterase (Ashiq et al., 2009), urease
(Ara et al., 2007) and carbonic anhydrase (Scozzafava and
Supuran, 1997; Supuran et al., 1997) inhibition; metal ions
and complexes may also display antifungal (Maqsood et al.,
2006) and antioxidant (Ashiq et al., 2008, 2009; Qurrat-
ul-Ain et al., 2013) properties. However, enzyme inhibition
studies on Pd(II) complexes are rare. This study evaluates
the alpha-glucosidase inhibition potential of Pd(II) hydrazidecomplexes, which could lead to the improvement of postpran-
dial hyperglycemia and identification of new carbonic anhy-
drase inhibitors to control the effects of cancer, glaucoma
and neurological disorders.
2. Materials and methods
2.1. Chemistry
All the chemicals were of reagent grade, purchased from BDH,
Merck or Sigma–Aldrich and used without further purifica-
tion. A Shimadzu 460 IR spectrophotometer was employed
to record FT-IR spectra at 400–4000 cm1 on KBr disks. 1H
NMR and 13C NMR spectra in freshly prepared DMSO solu-
tions were obtained from a Bruker 300 spectrometer at 300 or
400 MHz using TMS as internal standard. EI-mass data of
ligands were collected from a Finnigan MAT 311-A apparatus.
A Sherwood MSB Mk1 magnetic susceptibility balance was
utilized to measure effective magnetic moments of powdered
complexes at room temperature using sealed-off MnCl2 solu-
tion as calibrant. CHN (elemental) analysis was carried out
on a Perkin Elmer 2400 series II CHN/ S analyzer. Pd contents
in complexes were analyzed by EDTA titration using sodium
nitrite as a selective masking agent in the presence of xylenol
orange indicator (Muralidhara et al., 1995). A Hanna (HI-
8633) conductivity meter was used for conductance measure-
ment. The carbonic anhydrase II was purchased from Sigma
Aldrich and substrate 4-nitrophenyl acetate from MP Bio
chemical company. HEPES buffer was obtained from
DOJINDO, Tris-(hydroxymethyl)-aminomethane (reagent
grade) from Scharlau and DMSO from Fischer Scientific
chemical company. The a-glucosidase enzyme (purified from
Saccharomyces Cerevisiae) and all other chemicals required
for a-glucosidase inhibition assay were also purchased from
Sigma Aldrich. IC50 values were calculated by using EZ-fit
enzyme kinetics software (USA).
2.1.1. General procedure for the synthesis of the hydrazide
ligands
Hydrazide ligands were synthesized from corresponding esters
(Scheme 1). The ethyl or methyl esters were first obtained on
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in ethanol for 5–6 h followed by extraction in chloroform.
After solvent evaporation, the esters (66 mmol) and hydrazine
hydrate (330 mmol) were refluxed in 75 ml ethanol for 4–5 h.
The solvent from resulting mixture was evaporated on rotary
evaporator to get a colorless solid product. The hydrazide pro-
duct was finally washed and dried in air. The relevant spectral
and elemental data are given below.
2.1.1.1. 2-Fluorobenzohydrazide (1). Colorless solid. Anal.
Calcd. for C7H7N2OF (FW= 154 gmol
1): C, 54.54; H,
4.54; N, 18.18%. Found: C, 54.58; H, 4.56; N, 18.15%.
FTIR (KBr cm1): 1674 (C‚O), 3288, 3206 (NH2 stretch.),
3037 (NH), 1616 (NH2 bend.), 1567 (C‚C), 1343 (CAN),
1228 (CAO), 1098 (NAN). 1H NMR (400 MHz, DMSO):
d(ppm) = 9.49 (s, 1H, NH), 7.60 (dd, 1H, J= 5.5 Hz,
J= 2.4 Hz, H-6), 7.56 (dt, 1H, J= 6.8 Hz, J= 2.0 Hz,
H-4), 7.50 (dt, 1H, J= 6.6 Hz, H-3), 7.26 (dd, 1H,
J= 8.0 Hz, J= 2.8 Hz, H-5), 4.52 (s, 2H, NH2).
13C NMR
(400 MHz, DMSO): d(ppm) = 163.27 (C‚O), 115.91–160.27
(ArAC). EI MS: 154 (19, M+), 124 (8), 123 (100), 95 (35),
75 (7).
2.1.1.2. 3-Fluorobenzohydrazide (2). Colorless solid. Anal.
Calcd. for C7H7N2OF (FW= 154 gmol
1): C, 54.54; H,
4.54; N, 18.18%. Found: C, 54.57; H, 4.53; N, 18.11%.
FTIR (KBr cm1): 1663 (C‚O), 3300, 3219 (NH2 stretch.),
3026 (NH), 1620 (NH2 bend.), 1585 (C‚C), 1349 (CAN),
1232 (CAO), 1009 (NAN). 1H NMR (400 MHz, DMSO):
d(ppm) = 9.85 (s, 1H, NH), 7.67 (d, 1H, J= 8.0 Hz, H-6),
7.59 (dd, 1H, J= 10.4 Hz, J= 2.0 Hz, H-2), 7.49 (dd, 1H,
J= 6.0 Hz, J= 2.0 Hz, H-5), 7.34 (dt, 1H, J= 8.8 Hz,
J= 2.8 Hz, H-4), 4.51 (s, 2H, NH2).
13C NMR (400 MHz,
DMSO): d(ppm) = 164.38 (C‚O), 113.51–163.06 (ArAC).
EI MS: 154 (47, M+), 124 (15), 123 (100), 95 (95), 75 (47),
57 (4), 51 (13).
2.1.1.3. 4-Fluorobenzohydrazide (3). Colorless solid. Anal.
Calcd. for C7H7N2OF (FW= 154 gmol
1): C, 54.54; H,
4.54; N, 18.18%. Found: C, 54.60; H, 4.57; N, 18.20%.
FTIR (KBr cm1): 1661 (C‚O), 3303, 3223 (NH2 stretch.),
3023 (NH), 1620 (NH2 bend.), 1564 (C‚C), 1350 (CAN),
1243 (CAO), 997 (NAN). 1H NMR (300 MHz, DMSO):
d(ppm) = 9.75 (s, 1H, NH), 7.87 (dd, 2H, J= 4.8 Hz,
J= 3.9 Hz, H-2/H-6), 7.26 (dt, 2H, J= 8.1 Hz, J= 2.1 Hz,
H-3/H-5), 4.47 (s, 2H, NH2).
13C NMR (400 MHz, DMSO):
d(ppm) = 164.40 (C‚O), 114.53–164.28 (ArAC). EI MS:
154 154 (9, M+), 124 (8), 123 (100), 95 (93), 75 (35), 57 (4),
51 (11).
2.1.1.4. 4-Phenylsemicarbazide (4). Colorless solid. Anal.
Calcd. for C7H9N3O (FW= 151 gmol
1): C, 55.62; H, 5.96;
N, 27.81%. Found: C, 55.64; H, 5.98; N, 27.86%. FTIR
(KBr cm1): 1687 (C‚O), 3362, 3260 (NH2 stretch.), 3094
(NH), 1595 (NH2 bend.), 1540 (C‚C), 1302 (CAN), 1226
(CAO), 925 (NAN). 1H NMR (400 MHz, DMSO):
d(ppm) = 8.57 (s, 1H, NH), 7.49 (d, 2H, J= 7.8 Hz, H-2/
H-6), 7.33 (s, 1H, phNHCO), 7.21 (t, 2H, J= 7.8 Hz, H-3/
H-5), 6.90 (t, 1H, J= 7.2 Hz, H-4), 4.31 (s, 2H, NH2).
13C
NMR (400 MHz, DMSO): d(ppm) = 157.28 (C‚O),
118.05–139.87 (ArAC). EI MS: 151 (61, M+), 120 (15), 119
(25), 92 (41), 77 (100), 65 (49), 51 (35).2.1.1.5. 2-Phenylacetohydrazide (5). Colorless solid. Anal.
Calcd. for C8H10N2O (FW= 150 gmol
1): C, 64.76; H, 6.66;
N, 18.66%. Found: C, 64.73; H, 6.68; N, 18.67%. FTIR
(KBr cm1): 1643 (C‚O), 3295, 3200 (NH2 stretch.), 3030
(NH), 1566 (NH2 bend.), 1529 (C‚C), 1352 (CAN), 1265
(CAO), 997 (NAN). 1H NMR (400 MHz, DMSO):
d(ppm) = 9.19 (s, 1H, NH), 7.23–7.28 (m, 5H, H-2/H-3/H-4/
H-5/H-6), 3.56 (s, 2H, phCH2CO), 4.19 (s, 2H, NH2).
13C
NMR (400 MHz, DMSO): d(ppm) = 168.94 (C‚O), 136.19
(phCH2), 125.74–128.34 (ArAC). EI MS: 150 (36, M
+), 137
(2), 120 (2), 118 (51), 106 (5), 91 (100), 77 (14), 65 (51), 51 (54).
The analytical data of 2-Methoxybenzohydrazide (6),
3-Methoxybenzohydrazide (7), 4-Methoxybenzohydrazide (8)
were reported previously (Qurrat-ul-Ain et al., 2013), whereas
2-Chlorobenzohydrazide (9), 3-Chlorobenzohydrazide (10)
and 4-Chlorobenzohydrazide (11) will be reported elsewhere.
2.1.2. General procedure for the synthesis of the palladium(II)-
hydrazide complexes
Two complexes (1b and 2b) were synthesized in water, while
remaining complexes (3b–5b) were prepared in acetonitrile.
30 ml solution of palladium(II) chloride (1 mmol) in acetoni-
trile or water containing one drop of concentrated HCl was
mixed slowly with 30 ml solution of hydrazide (2 mmol) in
the same solvent. The yellow precipitates started forming
immediately, which were kept on stirring for about 3 h at room
temperature. The yellow solid complex was then separated,
washed with water or acetonitrile and finally allowed to dry
in air. The physical, elemental and spectral data of complexes
1b–5b are presented below.
2.1.2.1. Dichlorobis(2-fluorobenzohydrazide)palladium(II)
[Pd(2-fbh)2Cl2] (1b). Yellow solid. Anal. Calcd. for
C14H14N4O2F2Cl2Pd (FW= 485.70 gmol
1): C, 34.60; H,
2.88; N, 11.54; Pd, 21.92%. Found: C, 33.52; H, 2.13; N,
10.13; Pd, 22.01%. FTIR (KBr cm1): 1666 (C‚O), 3372
(NH2 stretch.), 3208 (NH), 1615 (NH2 bend.), 1526 (C‚C),
1309 (CAN), 1212 (CAO), 1099 (NAN). 1H NMR
(400 MHz, DMSO): d(ppm) = 9.58 (s, 1H, NH), 7.24–7.72
(Aromatic-H), 4.95 (s, 2H, NH2).
13C NMR (400 MHz,
DMSO): d(ppm) = 160.59 (C‚O), 115.61–159.72 (ArAC).
Molar conductivity (DMSO): 5.12 X1 cm2 mol1. Effective
magnetic moment: 0.198 B.M. Yield: 78.50%.
2.1.2.2. Dichlorobis(3-fluorobenzohydrazide)palladium(II)
[Pd(3-fbh)2Cl2] (2b). Yellow solid. Anal. Calcd. for
C14H14N4O2F2Cl2Pd (FW= 485.70 gmol
1): C, 34.60; H,
2.88; N, 11.54; Pd, 21.92%. Found: C, 33.94; H, 2.01; N,
10.88; Pd, 21.25%. FTIR (KBr cm1): 1655 (C‚O), 3270,
3196 (NH2 stretch.), 3100 (NH), 1604 (NH2 bend.), 1585
(C‚C), 1329 (CAN), 1215 (CAO), 948 (NAN). 1H NMR
(400 MHz, DMSO): d(ppm) = 9.99 (s, 1H, NH), 7.36–7.68
(Aromatic-H), 5.29 (s, 2H, NH2).
13C NMR (400 MHz,
DMSO): d(ppm) = 164.44 (C‚O), 113.61–163.48 (ArAC).
Molar conductivity (DMSO): 9.09 X1 cm2 mol1. Effective
magnetic moment: 0.219 B.M. Yield: 84.15%.
2.1.2.3. Dichlorobis(4-fluorobenzohydrazide)palladium(II)
[Pd(4-fbh)2Cl2] (3b). Yellow solid. Anal. Calcd. for
C14H14N4O2F2Cl2Pd (FW= 485.70 gmol
1): C, 34.60; H,
2.88; N, 11.54; Pd, 21.92%. Found: C, 34.32; H, 2.56; N,
Studies of Pd(II)-hydrazide complexes 49111.45; Pd, 20.85%. FTIR (KBr cm1): 1604 (C‚O), 3310,
3203 (NH2 stretch.), 3106 (NH), 1604 (NH2 bend.), 1535
(C‚C), 1326 (CAN), 1238 (CAO), 905 (NAN). 1H NMR
(400 MHz, DMSO): d(ppm) = 9.94 (s, 1H, NH), 7.23–7.88
(Aromatic-H), 5.49 (s, 2H, NH2).
13C NMR (400 MHz,
DMSO): d(ppm) = 164.33 (C‚O), 114.64–162.63 (ArAC).
Molar conductivity (DMSO): 2.08 X1 cm2 mol1. Effective
magnetic moment: 0.147 B.M. Yield: 88.90%.
2.1.2.4. Dichlorobis(4-phenylsemicarbazide)palladium(II)
[Pd(4-psc)2Cl2] (4b). Yellow solid. Anal. Calcd. for
C14H18N6O2Cl2Pd (FW= 479.76 gmol
1): C, 35.01; H, 3.75;
N, 17.52; Pd, 22.18%. Found: C, 35.00; H, 3.50; N, 16.95;
Pd, 21.17%. FTIR (KBr cm1): 1681 (C‚O), 3450, 3339
(NH2 stretch.), 3197 (NH), 1643 (NH2 bend.), 1603 (C‚C),
1320 (CAN), 1257 (CAO), 1030 (NAN). 1H NMR
(400 MHz, DMSO): d(ppm) = 9.26 (s, 1H, NH), 6.99–7.82
(Aromatic-H), 7.35 (s, 1H, phNHCO), 6.47 (s, 2H, NH2).
13C NMR (400 MHz, DMSO): d(ppm) = 154.33 (C‚O),
117.93–138.99 (ArAC). Molar conductivity (DMSO):
12.42 X1 cm2 mol1. Effective magnetic moment: 0.132 B.M.
Yield: 88.90%.
2.1.2.5. Dichlorobis(2-Phenylacetohydrazide)palladium(II)
[Pd(2-pah)2Cl2] (5b). Yellow solid. Anal. Calcd. for
C16H20N4O2Cl2Pd (FW= 477.78 gmol
1): C, 40.21; H, 4.19;
N, 11.73; Pd, 22.29%. Found: C, 40.38; H, 3.78; N, 11.77;
Pd, 21.97%. FTIR (KBr cm1): 1650 (C‚O), 3322, 3198
(NH2 stretch.), 3116 (NH), 1602 (NH2 bend.), 1547 (C‚C),
1357 (CAN), 1268 (CAO), 1077 (NAN). 1H NMR
(400 MHz, DMSO): d(ppm) = 9.80 (s, 1H, NH), m7.26
(Aromatic-H), 6.63 (s, 2H, NH2), 3.57 (s, 1H, phCH2CO).
13C NMR (400 MHz, DMSO): d(ppm) = 168.95 (C‚O),
136.19 (phCH2), 126.00–128.57 (ArAC). Molar conductivity
(DMSO): 3.90 X1 cm2 mol1. Effective magnetic moment:
0.153 B.M. Yield: 82.25%.
2.2. a-Glucosidase inhibition
The in vitro a-glucosidase inhibition assay was performed by
spectrophotometric method described by Dewi et al., 2007
with slight modifications, involving hydrolysis of substrate p-
nitrophenyl a-D-glucopyranoside according to Scheme 2
(Srianta et al., 2013).
The enzyme a-glucosidase was dissolved in a buffer of pH
6.8 containing 3 mM sodium phosphate and 6 mM NaCl. In
a 96-well plate reader, a reaction mixture comprising 20 ll of
varying concentrations (0.02–10 lM) of sample dissolved
in DMSO (4.6% final concentration) and 100 ll of alpha-
glucosidase (1 U/ml) was pre-incubated for 5 min at 37 C,Scheme 2 Mechanism of hydrolysis of p-nitrophenyland then 260 ll of 0.5 mM p-nitrophenyl a-D-glucopyranoside
was added to the mixture. After further incubation at 37 C for
30 min, the reaction was terminated by adding 70 ll of sodium
carbonate (0.1 M). The yellow color produced (due to
p-nitrophenol formation) was quantitated by measuring the
absorbance at 400 nm. The standard 1-deoxynojirimycin
was used as a positive control. The % inhibition was obtained
using the formula: % inhibition = [{Absorbance(control)
Absorbance(sample)}/Absorbance(control)] * 100. Each experiment
was performed in triplicates. The IC50 (i.e., the concentration of
sample inhibiting 50% of alpha-glucosidase activity under the sta-
ted assay conditions) data of Pd(II) hydrazide complexes, metal
salt and standard are given in Table 1.
2.3. Carbonic anhydrase inhibition
In this assay, colorless 4-nitrophenyl acetate (4-NPA) is hydro-
lyzed to 4-nitrophenol and CO2, and the reaction is followed
by measuring the formation of 4-nitrophenol, a yellow colored
compound (Pocker and Meany, 1967).
The assay was carried out at 25 C in 20 mM HEPES-Tris
buffer of pH 7.4. Each sample tube comprised 140 ll of
HEPES-Tris buffer solution, 20 ll of fresh enzyme solution
(0.1 mg/ml in deionized water) of purified bovine erythrocyte
CA-II and 20 ll of test compound in DMSO (10% final con-
centration) at varying concentrations (3–500 lM). The enzyme
and inhibitor together in mixture solution were preincubated
for 15 min at room temperature to allow the formation of EI
complex. After incubation, the reaction with substrate was
initiated by adding 20 ll ethanolic solution (0.7 mM) of 4-
NPA. It was followed by continuous measurement of amount
of product formed at 400 nm for 30 min at 1 min interval in
96-well flat bottom plates, using ELISA Reader SPECTRA-
Max 340 spectrophotometer, Molecular Devices (USA). The
activity of control (in the absence of inhibitor) was taken as
100%. The measurements were taken in triplicates at each used
concentration (Shank et al., 2005; Arslan, 2001).
2.3.1. Enzyme kinetic studies
To determine the kinetic parameters, the substrate (4-nitro-
phenyl acetate) was used at four different concentrations
(0.18–1.4 mM). The solution of potential inhibitors, identified
by low IC50 values, was added to the reaction medium at
various concentrations under assay conditions stated above,
resulting in at least three different fixed concentrations
(3–50 lM) of inhibitors (Pocker and Meany, 1967).
A Lineweaver–Burk plot was generated to identify the type
of inhibition. The Michaelis–Menten constant (Km) value was
obtained from Lineweaver–Burk plot between reciprocal of the
substrate concentration (1/[S]) and reciprocal of enzyme ratealpha-D-glucopyranoside (pNPG) by a-glucosidase.
492 Qurrat-ul-Ain et al.(1/V) over different inhibitor concentrations. To determine
inhibition constant (Ki), a secondary re-plot of the inhibitor
concentration ([I]) versus the slope (i.e., Km/Vmax) was con-
structed. The Dixon plot between [I] and 1/V was drawn to
further confirm the Ki value and the type of inhibition of CA
II (Cornish-Bowden, 1974).
2.3.2. Statistical analysis
Grafit 7.0 version was used to determine the kinetic parame-
ters. The software was purchased from Erithacus Software
Ltd. Wilmington House, High Street, East Grinstead, West
Sussex RH19 3AU, UK.
3. Results and discussion
3.1. Synthesis and physicochemical properties
The synthesis of hydrazide ligands 1–11 was carried out
according to Scheme 1; these molecules were subsequently
complexed with Pd(II) to synthesize respective complexes
(1b–11b). Five ligands (1–5) were characterized spectroscopi-
cally (IR, 1H NMR, 13C NMR, EI-mass) and micro-analyti-
cally (CHN), as presented in the experimental section. The
structures of complexes 1b–5b are depicted in Fig. 1 and were
assigned based on their physical, chemical and spectral mea-
surements presented in experimental part; the data for 6b–8b
have been reported previously (Qurrat-ul-Ain et al., 2013),
and the data for 9b–11b will be reported elsewhere. All of
the Pd(II) complexes were amorphous, non-hygroscopic,
yellow-colored, and fairly stable at room temperature. The
complexes were highly soluble in coordinating solvents, such
as DMF, DMSO and THF; however, the complexes revealed
poor solubility in other solvents, such as water, acetone,
methanol and ethanol.
The sharp, well-defined signals for the Pd(II) complexes in
the NMR spectra reveal the diamagnetic nature of different
complexes which is also supported by low magnetic moments
(0.132–0.219 BM). Based on these studies we tentatively pro-
pose a square planar geometry (Fig. 1) for these complexes
(Blanchard et al., 2005). All of the ligands exhibited monoden-
tate behavior to form 1:2 metal–ligand complexes with Pd(II).
Two chloride ions were also present within the coordination
sphere. Ligands 1–5 coordinate to the metal via their terminal
nitrogen. The complexes are likely to be the trans isomersFigure 1 Structures of palladium(II) complexes.because this configuration minimizes the steric hindrance
between the hydrazide ligands (Kealey et al., 2007).
Furthermore, the ligands ensure that the trans isomers remain
separate by minimizing any possible cis–trans isomerism
caused by steric effects (Abu-Surrah et al., 2002). The insolu-
bility of Pd(II)-hydrazide complexes in polar solvents (water,
methanol, etc.) also supports the trans nature of complexes.
The trans complexes, being symmetrical, are non-polar, and
thus they have poor solubility in polar solvents (Ebbing and
Steven, 2010).
Freshly prepared DMSO solutions of complexes 1b–5b
possessed low ranging molar conductivities (2.08–
12.42 X1 cm2 mol1), suggesting they are non-electrolytic
(Teotia et al., 1973). The complexes were assumed to have
the general formula [PdL2Cl2], as indicated by the CHN and
Pd contents reported in experimental section.3.2. Spectroscopy
3.2.1. IR spectroscopy
The IR vibrational data for hydrazide ligands 1–5 and their
palladium(II) complexes 1b–5b are provided in experimental
section. A pair of intense peaks at 3200 and 3362 cm1 was
exhibited by all ligands, and these peaks are attributed to the
N-H asymmetric and symmetric stretching modes of the
terminal hydrazinic amino group (Singh et al., 2005). After
complexation to form 1b–5b, these bands were shifted signifi-
cantly toward higher or lower wavenumbers relative to the free
ligands. Therefore, the terminal amino nitrogen coordinates
with palladium(II) in ligands 1–5 (Adeoye et al., 2007; Abd
El Wahed et al., 2004).
The strong carbonyl stretching absorption band occurs at
1665 ± 22 cm1 in the ligands; this band is near the amide car-
bonyl absorptions (1655 ± 15 cm1) (Singh et al., 2005;
Adeoye et al., 2007). Each of the ligands (1–5) exhibited only
a small decrease in the carbonyl absorption band after com-
plexation, suggesting that coordination did not occur through
the carbonyl oxygen. The bands assigned to the NH2 bending,
as well as the CAN, CAO, NAN, and the aromatic C‚C
stretching (Ziolo et al., 1971; Basu et al., 1999; Piotr et al.,
2005; Sharma et al., 2009; Pradeep et al., 2008; Chohan and
Praveen, 1999) are also reported in experimental section.
The hydrazinic imino group in the ligands also generated a
sharp band at 3058 ± 35 cm1 (Singh et al., 2005) that shifts
only slightly after complexation because the palladium(II)
coordinates with the neighboring amino group. The IR vibra-
tional data suggested that the ligands were monodentate. In
complexes 1b–5b, the coordination site might be the terminal
hydrazinic amino nitrogen.
The sharp bands appeared in the FT-IR spectra of Pd(II)-
hydrazide complexes advocate their trans geometry
(Mukherjee et al., 2011). The vibrational spectra revealed a
single sharp band at 530–540 cm1 corresponding to Pd-N
symmetric stretching for Pd(II)-hydrazide complexes, which
further confirms the trans geometry of complexes (Lubna
et al., 2014; Mukherjee et al., 2011). The sharp and well defined
–NH stretching bands are sometimes assigned to hydrogen
bonded –NH groups (Pavia et al., 2001). In present case, it is
assumed that the intramolecular hydrogen bonding may exist
between –NH and fluoro/carbonyl groups in the same hydra-
zide ligand (orienting trans to other hydrazide) instead of
Table 1 a-Glucosidase inhibition activity of palladium(II) complexes 1b–11b.
Compound IC50 (lM) Compound IC50 (lM)
1b 0.20 ± 0.005 8b 0.63 ± 0.002
2b 0.58 ± 0.002 9b 0.40 ± 0.001
3b 0.09 ± 0.001 10b 1.11 ± 0.008
4b 0.79 ± 0.008 11b 1.06 ± 0.005
5b 1.20 ± 0.009 PdCl2 0.45 ± 0.001
6b 0.85 ± 0.005 DNJ 300 ± 1.72
7b 1.12 ± 0.007 – –
DNJ = 1-Deoxynojirimycin, the standard inhibitor of a-glucosidase.
Studies of Pd(II)-hydrazide complexes 493hydrogen bonding between two adjacent hydrazides in cis
configuration.
3.2.2. 1H NMR spectroscopy
The 1H NMR spectral data of the hydrazide ligands (1–5) and
their complexes (1b–5b) are presented in experimental section.
The signal assigned to the terminal amino protons appeared
between 4.19 and 4.52 ppm for the ligands and shifted down-
field after complexation to form 1b–5b, indicating that the
amino nitrogen coordinates with Pd(II) in these complexes
(Abd El Wahed et al., 2004). The singlet at 8.57–9.99 ppm
for the ligands and their complexes was attributed to the imino
NH group, suggesting that the ligands exist in their keto (pro-
tonated) form in DMSO even after complexation and therefore
cannot directly coordinate to Pd(II) via the imino NH
(Sunirban and Samudranil, 2006). The negligible shift after
complexation for the imino NH signal for all of the ligands
further supports that the imino NH group is unavailable for
coordination. Therefore, the 1H NMR spectral results agree
with the IR results. The aromatic proton NMR signals for
ligands 1–5 validate the 6.89–7.91 ppm chemical shifts
(Abdul et al., 2011; Pradeep et al., 2008). In the complexes,
the aromatic protons’ resonances generally have higher chemi-
cal shift values because there is increased conjugation after
complexation (Ballhausen and Gray, 1962).
3.2.3. 13C NMR spectroscopy
The 13C NMR spectral data for free ligands and respective
Pd(II) complexes are displayed in experimental section and
validate the bonding modes evident in the IR and 1H NMR
spectral studies discussed above. The number of carbon peaks0 
15
30
45
60
75
90
0 0.5 1 1.5 2 2.5
%
 In
hi
bi

on
Concentraon (μM)
1b
2b
3b
4b
Figure 2a a-Glucosidase inhibition activity profile of Pd(II)
complexes 1b–4b.observed for the ligands and their respective complexes
matches the expected values. The aromatic carbon signals for
the ligands are within 113.51–164.28 ppm (Chohan and
Hanif, 2011) and shift slightly after complexation due to
changes in conjugation. The carbonyl carbon signals appear
at the furthest downfield position (Mishra and Soni, 2008)
within 157.28–168.94 ppm for ligands 1–5 (Kucukguzel et al.,
2003). The position of the carbonyl signal remained almost
same for the complexes (1b–5b), clearly excluding the possibil-
ity of carbonyl coordination in these complexes.
The electron density at the reactive site on each ligand
molecule depends on the polar properties of its substituents
when all other factors remain constant (Zhdanov and
Minkin, 1966). This aspect might explain the variable coordi-
nation behavior exhibited by various hydrazides toward
Pd(II). The amino nitrogen is a soft base and a stronger r-
donor relative to the carbonyl oxygen (Sunirban and
Samudranil, 2006). Therefore, because Pd(II) is a soft acid, it
usually prefers nitrogen instead of oxygen coordination, as
observed in complexes 1b–5b. However, the carbonyl group
is a relatively poor r-donor and a hard base; this functionality
might be a good p-electron acceptor if the electron density is
decreased to strengthen the metal–oxygen bond via p-back
bonding (Kuznetsov et al., 2006). Consequently, the hydra-
zides’ electronic and steric properties could be used to tune
their bonding mode toward the Pd(II) center.3.3. a-Glucosidase inhibition
The a-glucosidase inhibition activity data are reported in
Table 1, representing the IC50 values for Pd(II)-hydrazide0 
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Figure 2b a-Glucosidase inhibition activity profile of Pd(II)
complexes 5b–8b.
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Figure 2c a-Glucosidase inhibition activity profile of Pd(II)
complexes 9b–11b and Pd(II) chloride.
Table 2 Carbonic anhydrase II inhibition activity of palla-
dium(II) complexes.
Compound IC50 (lM) Compound IC50 (lM)
1b 446.18 ± 8.27 8b >500
2b 14.43 ± 0.91 9b 295.04 ± 2.05
3b 56.00 ± 1.56 10b 10.80 ± 0.46
4b >500 11b 240.7 ± 1.15
5b >500 PdCl2 17.34 ± 0.40
6b 17.07 ± 0.35 ACZ 0.12 ± 0.03
7b >500 – –
ACZ=Acetazolamide, the standard inhibitor of carbonic anhydrase.
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a-glucosidase inhibitor. Complexing the inactive ligands with
Pd(II) caused a noticeable increase in the a-glucosidase inhibi-
tory potential of ligands, highlighting the crucial role of the
Pd(II) metal center during enzyme inhibition. This study pre-
dicts the dose-dependent a-glucosidase inhibition caused by
the Pd(II)-hydrazide complexes; the inhibition activity
increased as the concentration of compound increased in the
tested range (Figs. 2a–c).
All of the Pd(II)-hydrazide complexes were highly potent
a-glucosidase inhibitors (IC50 = 0.09–1.20 lM) and were
approximately 300 times more active than the standard
a-glucosidase inhibitor, DNJ (IC50 = 300 lM). In the litera-
ture, there are plenty of examples of metal complexes with
various metal ions, which exhibit excellent a-glucosidase
inhibition efficacies (Yoshikawa et al., 2010; Hiromura and
Sakurai, 2008; Sakurai, 2008; Kiss et al., 2008; Ueda et al.,
2005; Thompson et al., 2003). a-Glucosidase inhibition activity
revealed by Pd(II)-hydrazide complexes is higher (lower IC50
values) than some potential antidiabetic zinc(II) complexes
studied by Ueda et al., 2005.
The precursor metal salt (PdCl2) was also an excellent
a-glucosidase inhibitor (IC50 = 0.45 lM). The results of pre-
sent study are in good accord with those obtained by Ueda
et al., 2005 for zinc(II) complex [Zn(6mpa-ma)2]SO4. The
ligand 6mpa-ma (i.e., 6-methyl-2-picolinmethylamide) was
completely inactive, while the respective zinc complex was
several times more efficient a-glucosidase inhibitor compared
to acarbose (standard medicine), and even the metal salt
(ZnCl2) was almost equally potent as resulting zinc complex.
The imidazole and carboxy groups have been documented
earlier as most closely related active site residues of
a-glucosidases (Chiba and Shimomura, 1979). The
palladium(II) ion, being a soft Lewis acid, may coordinate to
a-glucosidase through soft electron donors, such as imidazole
nitrogen, leading to inhibition of enzyme. Cornman et al., 1995
previously suggested that forming a bond between a metal ion
and a protein side chain might inhibit or activate enzymes.
The complexation of Pd(II) with inactive hydrazide ligands
modified its inhibition activity. Three ligands (1, 3 and 9)
strengthened the Pd(II)-complexes’ inhibitory effect relative
to the PdCl2, but eight ligands (2, 4–8, 10 and 11) decreased
the inhibitory potential of PdCl2 after complexation.
Therefore, the inactive ligand can increase or decrease the
enzyme inhibition activity of the precursor metal compound,which may be related to change in the structural or electronic
properties.
The nature and position of the substituents in the Pd(II)
complexes modulate the a-glucosidase inhibition. Complexes
containing fluoro (1b and 3b), methoxy (6b and 8b) and chloro
(9b and 11b) substituents at the ortho and para positions are
slightly stronger a-glucosidase inhibitors relative to the
corresponding meta-substituted complexes (2b, 7b and 10b).
Therefore, the Pd(II) complexes containing meta-substituents
attached to planar phenyl ring of hydrazides may interact less
favorably with a-glucosidase to inhibit the enzyme. Another
interesting feature is that the electron-withdrawing fluoro- and
chloro-substituted complexes (1b–3b and 9b–11b) exhibit a
slightly higher a-glucosidase inhibition than the electron-donat-
ing methoxy-substituted (6b–8b) complexes. Furthermore, the
CH2 group between the carbonyl group and the benzene ring
of the hydrazide ligand in complex 5b lowers the a-glucosidase
inhibition power more than complex 4b, which contains an
NH group in place of the CH2 group. It is therefore suggested
that the presence of electron withdrawing groups or electronega-
tive atoms (e.g., halogens or nitrogen) is responsible for greater
a-glucosidase inhibition abilities of Pd(II) complexes, probably
due to hydrogen bonding properties.
Zhou et al., 2006 established that the inhibitor’s hydrogen
bond-forming capabilities with the catalytic residue of a-glucosi-
dase in the inhibition action are important. There are numerous
hydrogen bond-donating or bond-accepting sites (NH/C‚O/
NH2) on the hydrazide moiety of the Pd(II) complexes; these
sites may H-bond with a-glucosidase, causing enzyme inhibition.
For acarbose and acarbose-like a-glucosidase inhibitors, Park
et al., 2008 revealed that the side chain of Thr 215 in a-glucosi-
dase is a hydrogen bond acceptor and the side chain hydroxyl
group on Ser244 is a hydrogen bond donor. The nature and
position of the substituents on the complexed hydrazide moiety
may influence the hydrogen bond-donating or bond-accepting
capabilities of the Pd(II) complexes.
Therefore, the presence of Pd(II) contributes to a-glucosi-
dase inhibition. The inhibitors may be stabilized further in
the active site by hydrogen bonding with the catalytic residues
and establishing cooperative hydrophobic contacts. Inhibition
might be modulated by the electronic effects that depend upon
the different substituents or groups in the inhibitor. Since the
Pd(II) compounds show several hundred fold more a-glucosi-
dase inhibition activity than the standard inhibitor (DNJ),
such effective a-glucosidase inhibitors of synthetic origin
may prove to be of importance in antidiabetic chemotherapy
and related disorders in future.
Figure 3a Kinetics of CA II inhibition by 10b. The Lineweaver–
Burk plot in the absence and presence of different concentrations
of 10b (lM): 0 (m), 3 (D) and 50 (s). It indicates mixed non-
competitive inhibition.
Figure 3b Kinetics of CA II inhibition by 10b. The secondary re-
plot of Lineweaver–Burk plot drawn between slope and various
concentrations of 10b. It gives inhibition constant (Ki).
Figure 3c Kinetics of CA II inhibition by 10b. The Dixon plot
for 10b in the presence of different concentrations of 4-NPA
substrate (mM): 0.18 (s), 0.35 (d) and 0.7 (h). It confirms Ki
value and mixed type non-competitive inhibition.
Table 3 Kinetics of the carbonic anhydrase II inhibition activity of palladium(II) complexes.
Sample code [I] (lM) Vmax (lM/min) Km (mM) Vmax (app) (lM/min) Km(app) (mM) Ki (lM) Type of inhibition
2b 12.5 73.52 2.91 16.58 1.70 9.45 Mixed-type inhibition
6b 50 82.64 3.6 103 7.43 27.11 Mixed-type inhibition
10b 50 73.52 2.91 25.31 1.71 25.2 Mixed-type inhibition
PdCl2 50 136.96 3.4 78.74 8.28 16.50 Mixed-type inhibition
ACZ 0.17 48.32 3.5 14.22 3.4 0.07 Noncompetitive
ACZ= Acetazolamide, the standard inhibitor of carbonic anhydrase.
[I] = Concentration of inhibitor, it is zero for columns Vmax and Km.
Vmax =Maximum velocity of enzymatic activity without inhibitor.
Vmax (app) =Maximum velocity of enzymatic activity in the presence of inhibitor at given concentration.
Km =Michaelis–Menten constant without inhibitor.
Km(app) =Michaelis–Menten constant in the presence of inhibitor at given concentration.
Ki = Inhibition constant calculated from secondary re-plot of Lineweaver–Burk plot.
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The IC50 values for the inhibition of the CA-II enzyme by pal-
ladium complexes are presented in Table 2. After screening
synthesized palladium metal complexes against CA, only a
few complexes revealed excellent inhibition, where the IC50
values ranged from 10.80 to 446.18 lM. Compounds 2b, 6b
and 10b were excellent inhibitors compared to a palladium salt.
The other compounds displayed weak inhibition.
The metal salt and its three complexes (2b, 6b and 10b) were
subjected to kinetics-based mechanistic studies to identify the
type of inhibition (Table 3). Determining the type of inhibition
is very important for identifying the inhibition mechanism and
interactions of the ligands with the enzymatic active site. The
graphical analysis of the steady state inhibition data for 10b
against carbonic anhydrase is presented in Figs. 3a–3c. The
Lineweaver–Burk plot identifies that all tested compounds
exhibit a mixed type non-competitive inhibition of CA II
with 4-NPA (substrate) since both Vmax and Km values are
changed (having an intersecting point) during the enzymatic
reaction in the presence of inhibitor (Dixon, 1953). Using
496 Qurrat-ul-Ain et al.Lineweaver–Burk plot, the values of Km (without inhibitor)
and Km(app) (in the presence of inhibitor) were obtained from
the intersection of abscissa, while 1/Vmax (without inhibitor)
and 1/Vmax(app) (in the presence of inhibitor) were obtained
from the intersection of ordinate. The secondary re-plot of
Lineweaver–Burk plot between slope (=Km/Vmax) and inhibi-
tor concentration gives inhibition or dissociation constant (Ki).
The larger Ki value reflects weaker binding of inhibitor to CA
II. The Dixon plot further confirms the Ki value and existence
of mixed type inhibition; the intersection point is not exactly
on [I] axis but nearer to x-axis in the Dixon plot, excluding
the presence of pure non-competitive inhibition (Dixon,
1953; Cornish-Bowden, 1974). The mixed inhibition dictates
the binding of Pd(II) compounds at a site other than the sub-
strate binding site in the active site cavity of CA II; for exam-
ple, Pd(II) may easily interact with sulfur or nitrogen donor
amino acids to inhibit the enzyme, similar to metal complexes
of sulfonamides (Briganti et al., 1997). In addition, a Pd(II)-
based CAI may bind both free enzyme and enzyme-substrate
(ES) complex, but having different affinity for one state or
the other (Storey, 2004). Lineweaver–Burk plot and Table 3
illustrate that in case of PdCl2 and 6b, there is a decrease in
the apparent affinity of the enzyme for the substrate
(Km(app) > Km), i.e., an increase in Km value in the presence
of inhibitor, showing that the PdCl2 and 6b favor binding
the free enzyme. In contrast, the compounds 2b and 10b show
an increase in the apparent affinity for the substrate
(Km(app) < Km), i.e., a decrease in the Km value in the presence
of inhibitor, indicating that these two inhibitors preferably
bind to ES complex (Storey, 2004).
The hydrazide ligands (1–11) exhibited no inhibition
against carbonic anhydrase. In contrast, the Pd(II) hydrazide
complexes revealed varied IC50 values (Table 2), indicating
excellent, moderate, and weak inhibition of carbonic anhy-
drase. These results were consistent with previous studies
describing CA inhibition caused by various metal (Zn2+,
Cd2+, Hg2+, Co2+, Ni2+, Cu2+, V4+, Fe3+, Ag+, Be2+,
Mg2+, and Al3+) complexes; all the metal complexes were
stronger inhibitors of CA relative to their parent ligands
(Scozzafava and Supuran, 1997; Supuran et al., 1997).
The precursor metal salt (PdCl2) is also a good CA inhibi-
tor (IC50 = 17.34 lM); however the complexation of the
hydrazide ligands with 3-fluoro (2), 2-methoxy (6) and 3-
chloro (10) substituents with Pd(II) further enhanced inhibi-
tory potential for their complexes (2b, 6b and 10b) relative to
the precursor metal; these CA inhibitors had IC50 values of
14.43, 17.07 and 10.80 lM, respectively. These IC50 values
were comparable to the standard inhibitor, ACZ
(IC50 = 0.12 lM). Complex 3b, which contained a 4-fluoro
group on the benzene ring of its hydrazide moiety, moderately
inhibited CA (IC50 = 56 lM), while 1b, 9b and 11b (2-fluoro,
2-chloro and 4-chloro substituents, respectively) exhibited
weak inhibition (IC50 = 446.18, 295.04 and 240.7 lM, respec-
tively). The remaining four complexes, 4b (NH group between
benzene ring and carbonyl groups), 5b (CH2 group between
benzene ring and carbonyl groups), 7b (3-methoxy substituent)
and 8b (4-methoxy substituent) were poor CA inhibitors with
IC50 values above 500 lM.
The results demonstrate that the presence of fluoro (1b–3b)
and chloro (9b–11b) substituents plays important role in pre-
senting CA inhibition properties to Pd(II) complexes. The halo
groups may contribute in the polarizability of the complexesthat would make it possible for halo complexes to interact with
the hydrophilic patch situated at the entrance of CA II active
site (Briganti et al., 1997).
The mechanism for carbonic anhydrase inhibition by the
metal complexes relative to their parent ligands is currently
unknown, but it has been hypothesized that their enhanced
inhibitory potential might be caused by two phenomena that
occur separately or in concert: (i) the dissociation of a metal
complex inhibitor to form hydrazides and Pd(II) ions (in
diluted solution), which allows both species to interact with
their respective binding sites and (ii) the direct interaction
between the undissociated Pd(II) complex and the enzyme,
specifically the hydrophilic portion near the entrance of the
CA II active sites (Briganti et al., 1997). In present case, since
the ligands themselves are inactive to inhibit the enzyme, it is
suggested that the later mechanism is more favorable to occur,
and the undissociated Pd(II)-hydrazide complex might be the
CA II inhibitory species. The similar mechanism to bind CA
I has previously been proposed by Borras et al. (1996) for
Ni(II) complexes of sulfonamides and hydrazine. Since kinetic
studies reveal mixed non-competitive inhibition, it is presumed
that the Pd(II) ion in the undissociated complex would interact
with histidine residues, especially the imidazole ring of His 64
(a proton shuttle group that has been described as a favorable
metal interaction site) (Magerum and Dukes, 1974; Steiner
et al., 1975). These considerations are in accord with studies
reported by Briganti et al. (1997) and Elbaum et al. (1996)
for metal complexes of sulfonamides. The chance of direct
coordination of hydrazide ligands to zinc(II) active site may
be ruled out because the observed mechanism is a non-com-
petitive type. However, there is a great possibility that the
ligand may involve in hydrogen bonding interactions through
its NH or carbonyl group with Thr199 residue present in the
hydrophobic cavity, similar to nitrate, cyanide and cyanates
(Liljas et al., 1994). Further research is necessary to elucidate
the actual mechanism of CA inhibition utilized by the Pd(II)
complexes and to develop Pd(II)-based diuretic, antiglaucoma,
antiobesity, antiulcer and/or anti-infective drugs.
4. Conclusions
We developed a series of Pd(II) hydrazide complexes that were
characterized using physical, chemical and spectral measure-
ments; these complexes exhibited a square planar geometry
and the general formula [PdL2Cl2]. Each of the Pd(II) com-
plexes demonstrated several hundred-fold higher a-glucosidase
inhibition activity than the standard inhibitor, 1-deoxynojir-
imycin. The development of effective synthetic a-glucosidase
inhibitors may prove important for anti-diabetic chemother-
apy and treatments for other related disorders. Some of the
Pd(II) complexes are also excellent carbonic anhydrase
inhibitors, making them interesting anti-glaucoma drug
candidates.
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